The company’s revenue from operations in the January-March 2024 period increased 15% YoY to Rs 4,944 crore and the board of directors have also recommended a final dividend of Rs 10 per share for the year FY24.
EBITDA for the fourth quarter stood at Rs 640 crore in the reporting March quarter, compared with Rs 488 crore in the same quarter a year earlier.
Here is what brokerages say about the Q4 results:
MacquarieThe global brokerage firm stated that the company was operationally in line with their estimates but hospital profitability showed a decline. PAT was driven by higher depreciation and amortization expenses. The hospital business EBITDA margin compressed 130 bps YoY and 70 bps QoQ to 23.1%.Macquarie has an ‘underperform’ rating for the stock with a target price of Rs 4,200.Motilal Oswal
Apollo Hospitals’ 4QFY24 revenue grew 15% YoY to Rs 49,40 crore against Motial’s estimates of Rs 4,870 crore while the EBITDA margin expanded 160bp YoY to 13% vs their estimate of 12.8%, due to lower RM costs/employee expenses/other expenses (down by 40/70bp/50bp YoY as a % sales).
Motilal will give a rating and the target price for the stock post the conference call which is due later today.
“FY24 has been a special year for us at Apollo as we achieved some remarkable milestones to further enhance the quality of our care. Our steadfast dedication to delivering top-notch healthcare services continues to be a key pillar of our growth,” said Prathap C Reddy, Chairman, Apollo Hospitals.
(Disclaimer: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of Economic Times)